AGEN Quote, Financials, Valuation and Earnings

Curis, Inc. has a net margin of -116.82% compared to Agenus, Inc.'s net margin of -243.36%. Agenus, Inc.'s return on equity of -- beat Curis, Inc.'s return on equity of -461.34%.

Agenus, Inc. has a consensus price target of $12.33, signalling upside risk potential of 332.75%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1196.3%. Given that Curis, Inc. has higher upside potential than Agenus, Inc., analysts believe Curis, Inc. is more attractive than Agenus, Inc..

Agenus, Inc. has a beta of 1.619, which suggesting that the stock is 61.86% more volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.

Agenus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.

Agenus, Inc. quarterly revenues are $30.2M, which are larger than Curis, Inc. quarterly revenues of $3.2M. Agenus, Inc.'s net income of $63.9M is higher than Curis, Inc.'s net income of -$7.7M. Notably, Agenus, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus, Inc. is 0.72x versus 1.03x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LadRx Corp. has a net margin of -116.82% compared to Agenus, Inc.'s net margin of --. Agenus, Inc.'s return on equity of -- beat LadRx Corp.'s return on equity of --.

Agenus, Inc. has a consensus price target of $12.33, signalling upside risk potential of 332.75%. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 434682.61%. Given that LadRx Corp. has higher upside potential than Agenus, Inc., analysts believe LadRx Corp. is more attractive than Agenus, Inc..

Agenus, Inc. has a beta of 1.619, which suggesting that the stock is 61.86% more volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.583%.

Agenus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus, Inc. pays -- of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend.

Agenus, Inc. quarterly revenues are $30.2M, which are larger than LadRx Corp. quarterly revenues of --. Agenus, Inc.'s net income of $63.9M is higher than LadRx Corp.'s net income of -$719.3K. Notably, Agenus, Inc.'s price-to-earnings ratio is -- while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus, Inc. is 0.72x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -116.82% compared to Agenus, Inc.'s net margin of -316.61%. Agenus, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.

Agenus, Inc. has a consensus price target of $12.33, signalling upside risk potential of 332.75%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1928.02%. Given that Plus Therapeutics, Inc. has higher upside potential than Agenus, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Agenus, Inc..

Agenus, Inc. has a beta of 1.619, which suggesting that the stock is 61.86% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Agenus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Agenus, Inc. quarterly revenues are $30.2M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Agenus, Inc.'s net income of $63.9M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Agenus, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus, Inc. is 0.72x versus 4.35x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Windtree Therapeutics, Inc. has a net margin of -116.82% compared to Agenus, Inc.'s net margin of --. Agenus, Inc.'s return on equity of -- beat Windtree Therapeutics, Inc.'s return on equity of -760.4%.

Agenus, Inc. has a consensus price target of $12.33, signalling upside risk potential of 332.75%. On the other hand Windtree Therapeutics, Inc. has an analysts' consensus of $4.0000 which suggests that it could grow by 43856.04%. Given that Windtree Therapeutics, Inc. has higher upside potential than Agenus, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Agenus, Inc..

Agenus, Inc. has a beta of 1.619, which suggesting that the stock is 61.86% more volatile than S&P 500. In comparison Windtree Therapeutics, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.733%.

Agenus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Windtree Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus, Inc. pays -- of its earnings as a dividend. Windtree Therapeutics, Inc. pays out 36.77% of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agenus, Inc. quarterly revenues are $30.2M, which are larger than Windtree Therapeutics, Inc. quarterly revenues of --. Agenus, Inc.'s net income of $63.9M is higher than Windtree Therapeutics, Inc.'s net income of -$28.1M. Notably, Agenus, Inc.'s price-to-earnings ratio is -- while Windtree Therapeutics, Inc.'s PE ratio is 0.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus, Inc. is 0.72x versus 0.26x for Windtree Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.